Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

224 patients over the age of 50 with a pertrochanteric hip fracture who had undergone fixation were randomized to 26 weeks of daily subcutaneous teriparatide 20ug or weekly oral risedronate 35mg. The purpose of this study was to compare measures of functional and clinical outcome, as well as safety outcomes and fracture healing over a 26-week follow-up. Results demonstrated significantly better Timed Up-and-Go results and pain scores during the TUG test up to 12 weeks and 18 weeks, respectively, in the teriparatide group compared to the risedronate group. By 26 weeks, differences between groups were non-significant. Hyperuricemia at 6 weeks and hypercalcemia at 26 weeks was significantly more frequent in the teriparatide group compared to the risedronate group. There were no significant differences in radiographic healing, mechanical failure of the implant, loss of reduction and nonunion between groups.